CELC Celcuity Inc.

QT17

Latest market price

69.72

+2.65+3.95%

Overview Short InterestFilings

CELCQT17Celcuity Inc.·NASDAQ

Overview Short InterestFilings

69.72+3.95%

Earnings

Up 4.0% — Earnings due 2026-11-05 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ELVN+0.45%$44.83 DYN+4.34%$18.05 VKTX-2.76%$26.09 TARS-0.93%$72.64 AMLX+4.14%$29.20 ACAD+0.49%$20.57 IDYA-0.98%$31.33 IRON+3.23%$81.16

Snapshot

Index	—	P/E	—	EPS (ttm)	-4.29	Insider Own	24.55%	Shs Outstand	48.93M	Perf Week	2.42%

Market Cap	3.28B	Forward P/E	—	EPS next Y	-2.47	Insider Trans	-25.81%	Shs Float	29.72M	Perf Month	-5.30%

Enterprise Value	3.28B	PEG	—	EPS next Q	-1.50			Short Float	34.50%	Perf Quarter	-24.97%

Income	-227.00M	P/S	—	EPS this Y	—			Short Ratio	9.23	Perf Half Y	-50.79%

Sales	0.00	P/B	—	EPS next Y	—	ROA	-27.35%	Short Interest	10.25M	Perf YTD	-30.10%

Book/sh	-0.27	P/C	4.35	EPS next 5Y	—	ROE	—	52W High	151.02 -53.83%	Perf Year	-9.64%

Cash/sh	15.41	P/FCF	—	EPS past 3/5Y	—	ROIC	-28.14%	52W Low	53.54 30.22%	Perf 3Y	605.67%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	5.20% 6.19%	Perf 5Y	291.47%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	4.00	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	8.93	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	50.85	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	8.93	EPS Q/Q	-38.46%	SMA20	7.64%	Beta	0.14	Target Price	157.67

Payout	0.00%	Debt/Eq	—	Sales Q/Q	—	SMA50	-9.12%	Rel Volume	0.92	Prev Close	67.07

Employees	155	LT Debt/Eq	—	Earnings	Nov 05	SMA200	-30.46%	Avg Volume	1.20M	Price	69.72

IPO Date	Sep 19, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.65% —	Net Debt/EBITDA	—	Volume	1,105,548	Change	3.95%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-22-26	Initiated	Cantor Fitzgerald	Overweight	$140
Aug-17-26	Reiterated	Guggenheim	Buy	$165 → $175
Aug-14-26	Reiterated	Needham	Buy	$157 → $140
Jul-15-26	Reiterated	Craig-Hallum	Buy	$171 → $178
Jul-15-26	Reiterated	HC Wainwright & Co.	Buy	$145 → $155
Jun-03-26	Reiterated	HC Wainwright & Co.	Buy	$185 → $145
Jun-03-26	Reiterated	Craig-Hallum	Buy	$189 → $171
Jun-03-26	Reiterated	Wells Fargo	Overweight	$183 → $166
Jun-02-26	Reiterated	Leerink Partners	Outperform	$155
May-28-26	Reiterated	Macquarie		$160

Latest News· Times ET

Today

Today08:30AM

Celcuity To Participate in Upcoming Investor Conferencesglobenewswire.com

Oct-30-26

Oct-30-2606:24AM

Celcuity: Stronger Clinical Evidence, Much Lower Valuationseekingalpha.com

Oct-29-26

Oct-29-2608:30AM

Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Callglobenewswire.com

Oct-25-26

Oct-25-2604:10PM

Will Breast And Prostate Cancer Data Change Celcuity (CELC) NarrativeYahoo

Oct-24-26

Oct-24-2604:15AM

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026globenewswire.com

Oct-23-26

Oct-23-2609:15AM

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026globenewswire.com

Oct-18-26

Oct-18-2603:11PM

Celcuity (CELC) Stock May Be Hard To Value On Book ValueYahoo

Oct-14-26

Oct-14-2606:05AM

New Strong Sell Stocks for October 14thzacks.com

Oct-07-26

Oct-07-2609:14PM

Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News EventYahoo

Oct-05-26

Oct-05-2608:00AM

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026globenewswire.com

Oct-02-26

Oct-02-2608:00AM

Celcuity Appoints David Gryska To Its Board Of Directorsglobenewswire.com

05:41AM

Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?defenseworld.net

Sep-30-26

Sep-30-2605:21PM

Why Celcuity Stock Was a Winner on Wednesdayfool.com

08:00AM

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United Statesglobenewswire.com

Sep-28-26

Sep-28-2612:59AM

Is Celcuity (CELC) Stock a Buy?Yahoo

Company

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	72	27	9	6	—	—	—	—	—
Research and Development	137	145	104	61	—	—	—	—	—
Other Operating Expense	-1	0	0	-1	—	—	—	—	—
Operating Income	-209	-172	-113	-66	—	—	—	—	—
Interest Expense	34	17	10	5	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	17	12	12	8	—	—	—	—	—
Net Income Before Taxes	-227	-177	-112	-64	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-227	-177	-112	-64	—	—	—	—	—
Net Income From Continuing Operations	-227	-177	-112	-64	—	—	—	—	—
Net Income	-227	-177	-112	-64	—	—	—	—	—
EPS (Recurring)	-4.29	-3.78	-2.83	-2.69	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-4.29	-3.78	-2.83	-2.69	—	—	—	—	—
EPS (Diluted)	-4.29	-3.78	-2.83	-2.69	—	—	—	—	—
EBITDA	-186	-160	-101	-58	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	55	53	39	24	—	—	—	—	—
Market Capitalization	3,835	5,286	511	350	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Furcht Leo	Director	Oct 07 '26	Option Exercise	7.60	250	1,900	12,780	Oct 09
BAKER BROS. ADVISORS LP	Former 10% owner	Jul 14 '26	Sale	102.50	3,100,000	317,750,000	442,940	Jul 16
Laing Lance G.	Chief Science Officer	Jun 02 '26	Option Exercise	9.89	1,000	9,890	1,251,000	Jun 04
Dalvey David	Director	May 04 '26	Sale	140.68	25,000	3,517,000	65,000	May 06
Buller Richard E	Director	May 04 '26	Option Exercise	5.10	9,000	45,900	15,760	May 06
Buller Richard E	Director	May 04 '26	Sale	140.46	9,000	1,264,181	6,760	May 06
Buller Richard E	Director	Mar 31 '26	Option Exercise	5.10	3,000	15,300	9,760	Apr 02
Buller Richard E	Director	Mar 31 '26	Sale	110.27	3,000	330,804	6,760	Apr 02
Dalvey David	Director	Jan 27 '26	Sale	120.03	20,000	2,400,538	90,000	Jan 29
Buller Richard E	Director	Dec 05 '25	Sale	105.69	3,000	317,069	6,760	Dec 09
Buller Richard E	Director	Dec 05 '25	Option Exercise	5.50	3,000	16,500	9,760	Dec 09
Furcht Leo	Director	Dec 04 '25	Option Exercise	7.60	250	1,900	11,000	Dec 08
Buller Richard E	Director	Dec 01 '25	Sale	98.13	1,100	107,948	7,260	Dec 03
Buller Richard E	Director	Dec 01 '25	Option Exercise	14.83	1,100	16,313	8,360	Dec 03
Dalvey David	Director	Nov 21 '25	Sale	100.00	15,000	1,500,017	110,000	Nov 24

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.